Immunopathogenesis of hypersensitivity syndrome reactions to sulfonamides

Translational Research

Volumn 149, Issue 5, 2007, Pages 243-253

  Neuman, Manuela G ^a,b   Shear, Neil H ^b,c   Malkiewicz, Izabella M ^a   Taeri, Masud ^a   Shapiro, Lori E ^c   Krivoy, Norberto ^d   Haber, Julia ^a,c   Gomez, Manuel ^c   Fish, Joel ^c   Cartotto, Robert ^c   Cohen, Lawrence ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHEMOKINE; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 2; RANTES; SULFONAMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL CELL; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYTOKINE RELEASE; EARLY DIAGNOSIS; FEMALE; FEVER; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOPATHOGENESIS; LYMPHOCYTE TOXICITY ASSAY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSICIAN; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RASH; RELIABILITY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOM; TH1 CELL;

EID: 34247484985     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2006.12.001     Document Type: Article

References (50)

1. Gruchalla R.S. Drug metabolism, danger signals, and drug-induced hypersensitivity. J Allergy Clin Immunol 108 (2001) 475-488
2. Moore N., Lecointre D., Noblet C., and Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 45 (1996) 301-308
3. Zimmerman H.J. Hepatotoxicity the adverse effects of drugs and other chemicals on the liver. 2nd ed. (1999), Lippincott Williams and Wilkins, Philadelphia, PA 498-509
4. Svensson C.K., Cowen E.W., and Gaspari A.A. Cutaneous drug reactions. Pharmcol Rev 53 (2000) 357-379
5. Knowles S.R., Uetrecht J., and Shear N.H. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 356 (2000) 1587-1591
6. Shear N.H., and Spielberg S. Anticonvulsant hypersensitivity syndrome. J Clin Invest 82 (1988) 1826-1832
7. Jones D., Chiap V., Resor S., and Grossman M. Phenytoin-like hypersensitivity associated with lamotrigine. J Acad Dermatol 36 (1997) 1016-1018
8. Svensson C.K., Cowen E., and Gaspari A.A. Cutaneous drug reactions. Pharmacol Rev 53 (2000) 357-379
9. Masters P.A., O'Bryan T.A., Zurlo J., Miller D.Q., and Joshi N. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 163 (2003) 402-410
10. Cribb A., Lee B., Trepanier L., and Spielberg S. Adverse reactions to sulfonamide and sulfonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 15 (1996) 9-50
11. Lazarou J., Pomeranz B., and Corey P. Incidence of adverse drug reactions in hospitalized patients. JAMA 279 (1998) 1200-1205
12. Jick J. A possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. Clin Exp Dermatol 22 (1982) 118-123
13. Schnyder B., Burkhart C., Shnyder-Frutig K., von Greyerz S., Naisbitt D.J., Pirmohamed M., et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol 164 (2000) 6647-6654
14. Smith K.J., Skelton H.G., Yeager J., Ledsky R., Hg T.H., and Wager K.F. Increased drug reactions in HIV-1-positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). Clin Exp Dermatol 22 (1997) 118-123
15. Coopman S.A., Johnson R.A., Platt R., and Stern R.S. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 328 (1993) 1670-1674
16. Krivoy N., Struminger L., Bendersky R., Avivi I., Neuman M.G., and Pollack S. Rifampin-induced thrombocytopenia: diagnosis by a novel in vitro lymphocyte toxicity assay. Isr Med Assoc J 3 (2001) 536
17. Sbeit W., Krivoy N., Shiller M., Furah R., Cohen H.I., Struminger L., et al. Nimesulide-induced acute hepatitis. Ann Pharmacother 35 (2001) 1049-1052
18. Neuman M.G., Malkiewicz I.M., and Shear N.H. A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clin Biochem 33 (2000) 517-524
19. Neuman M.G., Malkiewicz I.M., Phillips E.J., Rachlis A.R., Ong D., Yeung E., et al. Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals. Ther Drug Mon 24 (2002) 728-736
20. Cribb A., Miller M., Leeder J., Hill H., and Spielberg S. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Drug Metab Dispos 19 (1991) 900-906
21. Gill H.J., Hough S.J., Naisbitt D.J., Maggs J.L., Kitteringham N.R., Pirmohamed M., et al. The relationship between the disposition and immunogenicity of sulphamethozazole in the rat. J Pharmacol Exp Ther 282 (1997) 795-801
22. Naisbitt D.J., Gordon S.F., Pirmohamed M., Brurkhart C., Cribb A.E., Pichler W.J., et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenization and T-cell proliferaton in vivo. Br J Pharmacol 133 (2001) 295-305
23. Reilly T.P., and Ju C. Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions. Curr Opin Allergy Clin Immunol 2 (2002) 307-315
24. Reilly T.P., Lash L.H., Doll M.A., Hein D.W., Woster P.M., and Svesson C.K. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 114 (2000) 1164-1173
25. Rieder M., Uetrecht J., Shear N.H., Cannon M., and Miller M. Diagnosis of sulfonamide hypersensitivity reactions by in vitro "rechallenge" with hydroxylamine metabolites. Ann Inter Med 110 (1989) 286-289
26. Cribb A., and Spielberg S. Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine. Drug Metab Dispos 18 (1990) 784-787
27. Riley R.J., and Leeder J.S. In vitro anaylsis of metabolic predisposition to drug hypersensitivity reactions. Clin Exp Immunol 99 (1995) 1-6
28. Neuman M.G., Shear N.H., Bellentani S., and Tiribelli C. Role of cytokines in ethanol-induced hepatotoxicity in Hep G2 cells. Gastroenterol 114 (1998) 157-169
29. Mark D.B. Decision making in clinical medicine. In: Braunwald E., Fauci A.S., Kasper D.L., Hauser S.L., Longo D.L., and Jameson J.L. (Eds). Principles of internal medicine-Harrison's 15th ed (2001), McGraw-Hill, New York 8-14
30. Thurmann P.A., and Hompesch B.C. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 36 (1998) 586-590
31. Kotlyar M. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 37 (1999) 8-19
32. Rubin R.L., and Kretz-Rommel A. Phagocyte-mediated oxidation in idiosyncratic adverse drug reactions. Curr Opin Hematol 8 (2001) 34-40
33. Burner U., Furtmuller P.G., Kettle A.J., Koppenol W.H., and Obinger C. Mechanism of reaction of myeloperoxidase with nitrite. J Biol Chem 275 (2000) 20597-20601
34. Turnbull D.M., and Bindoff L.A. Muscle disease. In: Marshall W.J., and Bangert S.K. (Eds). Clincal biochemistry metabolic and clinical aspects (1995), Churchill Livingstone, New York 551-552
35. Dinarello C. Biologic basis for interleukin-1 in disease. Blood 87 (1996) 2095-2147
36. Tracey K., and Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 9 (1993) 317-343
37. Neuman M.G., Cameron R.G., Shear N.H., and Feuer G. Drug-induced apoptosis of skin cells and liver. In: Cameron R.G., and Feuer G. (Eds). Handbook of experimental pharmacology: apoptosis modulaton by drugs (1999), Springer Verlag Publishers, Heidelberg, Germany 344-355
38. Neuman M.G. Apoptosis in disease of the liver. Crit Rev Clin Lab Sci 38 (2001) 109-166
39. Neuman M.G. Apoptosis in liver disease. Rom J Gastroenterol 11 (2002) 3-7
40. Mizuhara H., O'Neill E., Seki N., Ogawa T., Kusunoki C., Otsuka K., et al. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 179 (1994) 1529-1537
41. Orange J., Salazar-Mather T., Opal S., and Biron C. Mechanism for virus-induced liver disease: tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection. J Virol 71 (1997) 9248-9258
42. Trauner M., Meier P., and Boyer J. Molecular pathogenesis of cholestasis. N Engl J Med 339 (1998) 1217-1227
43. Friedman S. Molecular regulation of hepatic fibrosis, and integrated cellular response to tissue injury. J Biol Chem 275 (2000) 2247-2250
44. Akerman P., Cote P.Y.S., McClain C., Nelson S., Bagby G.J., and White H.S. Antibodes to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol 263 (1992) G579-G585
45. Yamada Y., Kirillova I., Peschon J., and Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci USA 94 (1997) 1441-1446
46. Cressman D., Greenbaum L., DeAngelis R., Ciliberto G., Furth E., Poli V., et al. Liver failure and defective hepatocyte regeneration in interleukin-6-defecient mice. Science 274 (1996) 1379-1383
47. Ring J., and Brockow K. Adverse drug reactions: mechanisms and assessment. Eur Surg Res 34 (2002) 170-175
48. Neuman M.G., Shear N.H., Malkiewicz I.M., and Abbot F. P450's 2E1 inducers trigger valproic acid-induced apoptosis in vitro. [abstract]. Clin Invest Med 21 (1998) 582
49. Hess D.A., O'Leary E.F., Lee J.T., Almawi W.Y., Madrenas J., and Rieder M.J. Inhibition of cytokine production and interference in IL-2 receptor-mediated Jak-Stat signaling by the hydroxylamine metabolite of sulfamethoxazole. FASEB J 15 (2001) 1855-1857
50. Abe R., Shimizu T., Shibaki A., Nakamura H., Watanabe H., and Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 162 (2003) 1515-1520